The biotechnology company Editas hopes to begin clinical trials using the latest gene editing technique on human subjects in 2017, according to the company’s CEO Katrine Bosley. The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as plasmids and phages, and provides a form of acquired immunity.